Scientific Studies of Ca-EDTA
.
Ca-EDTA chelation therapy is the most studied therapy on the Planet. Here
are just 3 studies to take note of. We list only the abstracts here.
Ninety Percent Reduction in Cancer
Mortality
after Chelation Therapy With Ca-EDTA
Walter Blumer, M.D. and Elmer Cranton, M.D.
ABSTRACT: Mortality from cancer was reduced 90% during an 18-year follow-up of 59 patients treated with Calcium-EDTA. Only one of 59 treated patients (1.7%) died of cancer while 30 of 172 non-treated control subjects (17.6%) died of cancer (P=0.002). Death from artherosclerosis was also reduced. Treated patients had no evidence of cancer at the time of entry into this study. Observations relate only to long-term prevention of death from malignant disease, if chelation therapy is begun before clinical evidence of cancer occurs. Control and treated patients lived in the same neighborhood, adjacent to a heavily traveled highway in a small Swiss city. Both groups were exposed to the same amount of lead from automobile exhaust, industrial pollution and other carcinogens. Exposure to carcinogens was no greater for the studied population than exists in most other metropolitan areas throughout the world. Statistical analysis showed EDTA chelation therapy to be the only significant difference between controls and treated patients to explain the marked reduction in cancer mortality.
Benefits
of Ca-EDTA Chelation Therapy in Arteriosclerosis:
A retrospective study of 470 Patients
C. Hancke, MD, and K. Flytie, MD and Charles Farr, MD, PhD
ABSTRACT: In a retrospective study we reported results of EDTA chelation in 470 patients, using a number of parameters, most of them objective. Although the patients acted as their own control, we observed improvements of 80 to 91 %, depending on the measurements used. Of 92 patients referred for surgical intervention, only 10 required ultimate surgery after or during their chelation therapy, thus saving an estimated 3 million dollars of insurance money. Our experiences covers a period of 6 years and we saw no severe side effects or casualties arising from the treatment. We conclude that EDTA chelation therapy is safe, effective and cost-saving.
EDTA
Chelation Therapy III:
Treatment of Peripheral Arterial Occlusion, an Alternative to Amputation
H. Richard Casdorph, MD, PhD
ABSTRACT: Four patients are
presented, each of whom represents end-stage occlusive peripheral arterial
disease with gangrene of the involved extremity. These patients had exhausted
all traditional forms of therapy and they had all been referred for surgical
amputation. Instead of surgery, intravenous EDTA chelation therapy was
instituted with complete success in each case. These gangrenous extremities
all healed and were saved from amputation. Long-term follow up, extended
for more than a year, indicates that all four patients are continuing
to do well, with their previously gangrenous extremities intact and pain
free. Adjunctive therapies included vitamin and mineral supplementation
and, in two cases, hyperbaric oxygen therapy (HBO).
Kelatox: Only $199 for 30 suppositories.
Roughly Equivalent to 15 I.V. Sessions.
900 mg Ca-Edta per Suppository
Free Shipping in USA.
Back to Chelation by Suppository Homepage
Note: "The Food and Drug Administration have
not evaluated these statements.
This product is not intended to diagnose, cure, treat or prevent any disease.
Results will vary."
Copyright ©2003 Stephanie Relfe. All rights reserved.
